Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial

Xiaojuan Peng; Sisi Chen; Lu Zhong; Yuting Li; Chutian Wu; Lixian Zhong; Weiwei Chen; Jinying Yang; Jiahua Zeng; Shaohui Tang

doi:10.3389/fendo.2023.1176256

Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial

Front Endocrinol (Lausanne). 2023 May 24:14:1176256. doi: 10.3389/fendo.2023.1176256. eCollection 2023.

Authors

Xiaojuan Peng^{1

2

3}, Sisi Chen², Lu Zhong², Yuting Li², Chutian Wu², Lixian Zhong², Weiwei Chen², Jinying Yang², Jiahua Zeng², Shaohui Tang²

Affiliations

¹ Department of Endocrinology, Liuzhou People's Hospital, Liuzhou, Guangxi, China.
² Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
³ Department of Endocrinology, Affiliated Hospital of Xiangnan University, Chenzhou, Hunan, China.

Abstract

Objective: We aimed to investigate the effect of Cyclocarya paliurus leaves extracts (CP) on glucose and blood lipid metabolism and its relationship with intestinal flora in type 2 diabetes mellitus (T2DM) patients.

Methods: In this open-label, 84-day randomized controlled trial, a total of 38 T2DM patients were randomly assigned to the CP group or the Glipizide group (G group) in a 2:1 ratio. T2DM-associated metabolic phenotypes, gut microbiota and metabolites including short-chain fatty acids (SCFAs) and bile acids (BAs) were detected.

Results: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT glucose AUC)). Moreover, CP also resulted in the significant improvement in the levels of blood lipid and blood pressure. Notably, the improvement in blood lipid(triglycerides (TG) and high-density lipoprotein cholesterol (HDL-c)) and blood pressure (diastolic blood pressure (DBP)) was significantly greater in the CP group compared with the G group. Furthermore, the liver and kidney function parameters did not significantly change in both CP group and the G group over the 84-day period. Additionally, the enrichment of potentially beneficial bacteria (Faecalibacterium and Akkermansia), SCFAs and unconjugated BAs and the depletion of potential pathogenic bacteria (Prevotella_9) and conjugated BAs were observed in the CP group, while the abundances of the gut microbial were kept stable in the G group after intervention.

Conclusion: CP displays a more beneficial effect in the alleviation of T2DM-associated metabolic phenotypes than glipizide by regulating gut microbiota and metabolites in T2DM patients, with no significant effects on liver and kidney function.

Keywords: Cyclocarya paliurus leaves extracts (CP); gut microbiota; metabolic phenotypes; randomized controlled trial (RCT); type 2 diabetes mellitus (T2DM).

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / metabolism
East Asian People
Gastrointestinal Microbiome*
Glipizide / pharmacology
Glucose / pharmacology
Humans
Lipids
Plant Leaves / metabolism

Substances

Glipizide
Lipids
Glucose

Grants and funding

This study was supported by Natural Science Foundation of Hunan Province, China (No.2021JJ70048); Health Commission Funding Project of Hunan Province, China (No. B2019145); High-level talents scientific research start-up fund project of Liuzhou People’s Hospital, Guangxi (No. LRYGCC202202); Medical Science and Technology Foundation of Guangdong Province (No. A2018011, No. C2020076).